Valneva Gestion

Gestion contrôle des critères 1/4

Le PDG Valneva est Thomas Lingelbach, nommé en May2013, a un mandat de 11.5 ans. La rémunération annuelle totale est € 919.56K, composée du salaire de 58.8% et des bonus 41.2%, y compris les actions et options de la société. détient directement 0.24% des actions de la société, d'une valeur de € 790.37K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 0.9 ans et 1.7 ans.

Informations clés

Thomas Lingelbach

Directeur général

€919.6k

Rémunération totale

Pourcentage du salaire du PDG	58.8%
Durée du mandat du directeur général	11.5yrs
Propriété du PDG	0.2%
Durée moyenne d'occupation des postes de direction	less than a year
Durée moyenne du mandat des membres du conseil d'administration	1.7yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Thomas Lingelbach a-t-elle évolué par rapport aux bénéfices de Valneva?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-€7m
Jun 30 2024	n/a	n/a	-€32m
Mar 31 2024	n/a	n/a	-€24m
Dec 31 2023	€920k	€541k	-€101m
Sep 30 2023	n/a	n/a	-€113m
Jun 30 2023	n/a	n/a	-€7m
Mar 31 2023	n/a	n/a	-€135m
Dec 31 2022	€784k	€525k	-€143m
Sep 30 2022	n/a	n/a	€73m
Jun 30 2022	n/a	n/a	-€159m
Mar 31 2022	n/a	n/a	-€72m
Dec 31 2021	€769k	€420k	-€73m
Sep 30 2021	n/a	n/a	-€248m
Jun 30 2021	n/a	n/a	-€125m
Mar 31 2021	n/a	n/a	-€91m
Dec 31 2020	€649k	€376k	-€64m
Sep 30 2020	n/a	n/a	-€62m
Jun 30 2020	n/a	n/a	-€25m
Mar 31 2020	n/a	n/a	-€8m
Dec 31 2019	€1m	€384k	-€2m
Sep 30 2019	n/a	n/a	€4m
Jun 30 2019	n/a	n/a	€1m
Mar 31 2019	n/a	n/a	€7m
Dec 31 2018	€694k	€377k	€3m
Sep 30 2018	n/a	n/a	-€7m
Jun 30 2018	n/a	n/a	-€7m
Mar 31 2018	n/a	n/a	-€8m
Dec 31 2017	€649k	€367k	-€11m

Rémunération vs marché: La rémunération totale de Thomas ($USD 957.58K ) est dans la moyenne des entreprises de taille similaire sur le marché German ($USD 1.03M ).

Rémunération et revenus: La rémunération de Thomas a augmenté alors que l'entreprise n'est pas rentable.

PDG

Thomas Lingelbach (61 yo)

11.5yrs

Titularisation

€919,563

Compensation

Mr. Thomas Lingelbach has been the Chief Executive Officer of Valneva SE since May 2013 and served as its Chairman and Member of the Management Board since May 10, 2013 until December 20, 2023 and serves a...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Thomas Lingelbach	President	11.5yrs	€919.56k	0.24% € 790.4k
Peter Buhler	Chief Financial Officer	no data	€558.83k	0.028% € 91.7k
Franck Grimaud	Chief Business Officer	less than a year	€401.34k	0.39% € 1.3m
Juan-Carlos Jaramillo	Chief Medical Officer	less than a year	€539.76k	0.028% € 91.7k
Dipal Patel	Chief Commercial Officer	less than a year	€516.75k	pas de données
Vincent Dequenne	Chief Operating Officer	no data	pas de données	pas de données
Hanneke Schuitemaker	Chief Scientific Officer	less than a year	pas de données	pas de données
Joshua Drumm	Vice President of Investor Relations	3.3yrs	pas de données	pas de données
Laetitia Bachelot-Fontaine	VP of Global Communications & European Investor Relations	no data	pas de données	pas de données
Petra Pesendorfer	Chief People Officer	less than a year	pas de données	pas de données
Christian Taucher	Head of Global Medical Affairs	no data	pas de données	pas de données
Susanne Eder-Lingelbach	Head of Clinical Operations	no data	pas de données	pas de données

0.9yrs

Durée moyenne de l'emploi

53yo

Âge moyen

Gestion expérimentée: L'équipe de direction de AYJ0 n'est pas considérée comme expérimentée (ancienneté moyenne 0.9 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Thomas Lingelbach	President	less than a year	€919.56k	0.24% € 790.4k
James Sulat	Director	less than a year	€74.07k	0.019% € 62.2k
Alexander Von Gabain	Member of Scientific Advisory Board	4.8yrs	€10.00k	pas de données
James Connolly	Director	less than a year	€66.11k	pas de données
Kathrin Jansen	Director	less than a year	€28.25k	pas de données
Mailys Ferrere	Director	less than a year	pas de données	pas de données
George R. Siber	Member of Scientific Advisory Board	5yrs	pas de données	pas de données
Ralf Leo Clemens	Chair of Scientific Advisory Board	5.3yrs	€2.92k	pas de données
Norman Baylor	Member of Scientific Advisory Board	5yrs	pas de données	pas de données
Anne-Marie Graffin	Chairman	less than a year	€74.30k	0.0088% € 29.2k
Thomas Decker	Member of Scientific Advisory Board	2.5yrs	pas de données	pas de données
Michael Pfleiderer	Member of Scientific Advisory Board	2.5yrs	pas de données	pas de données

1.7yrs

Durée moyenne de l'emploi

65yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la AYJ0 n'est pas considéré comme expérimenté ( 1.7 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.

Valneva Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors

Valneva SE Announces Board Changes

Valneva Se Appoints Kathrin U Jansen to Supervisory Board

ValnevaSE Appoints Dipal Patel as Chief Commercial Officer

Valneva SE Announces Supervisory Board Member Appointments

Valneva Announces Board Appointments

Recent updates

Valneva and LimmaTech Announces First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva SE to Report Q1, 2025 Results on May 07, 2025

Valneva SE and LimmaTech Biologics AG Receives FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Valneva SE Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, Ixchiq

Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors

Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024

Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ

Valneva Se Announces Earnings Guidance for 2024

Valneva Se Announces the First Participant Has Been Vaccinated in the Phase 2 Clinical Trial Evaluating the Safety and Immunogenicity in Children of Two Different Dose Levels of Valneva’S Single-Shot Chikungunya Vaccine

Valneva SE to Report Fiscal Year 2023 Results on Mar 21, 2024

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE to Report Q1, 2024 Results on May 07, 2024

Valneva SE reported positive antibody persistence data twenty-four months after vaccination with a single dose of its chikungunya vaccine IXCHIQ®

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Valneva SE Announces Board Changes

Valneva SE Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ(R)

Valneva Se Provides Revenue Guidance for the Year 2023

Valneva SE Announces Positive Pediatric and Adolescent Immunogenicity and Safety Data for Their Lyme Disease Vaccine Candidate, VLA15

Health Canada Accepts Valneva's Chikungunya Vaccine License Application for Review

Valneva SE Reports Positive Initial Phase 3 Safety Data in Adolescents for Its Single-Shot Chikungunya Vaccine Candidate Vla1553

Valneva SE announced a financing transaction

Valneva Se Appoints Kathrin U Jansen to Supervisory Board

Valneva SE Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in the Lancet

Valneva SE Provides Financial Guidance of 2023

Pfizer Inc. and Valneva SE Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report First Half, 2023 Results on Aug 10, 2023

Valneva SE Reports Further Heterologous Booster Data from Exploratory, Small Clinical Study for its Inactivated COVID-19 Vaccine, VLA2001

Valneva Completes BLA Submission to U.S. FDA for Its Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report Q1, 2023 Results on May 04, 2023

Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate

Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

ValnevaSE Appoints Dipal Patel as Chief Commercial Officer

Valneva SE Reiterates Earnings Guidance for the Fiscal 2022

Valneva to Present on Its Single-Shot Chikungunya Vaccine Candidate At Leading Scientific Conferences

Valneva SE announced a financing transaction

Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001

Valneva SE Confirms World Health Organization Recommendations for its Inactivated COVID-19 Vaccine

Valneva SE Initiates Rolling Submission of U.S. Food and Drug Administration Biologics License Application for Its Single Shot Chikungunya Vaccine Candidate

Valneva SE Provides Revenue Guidance for the Fiscal Year 2022

Pfizer Inc. and Valneva SE Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Valneva Announces Initiation of the Phase 3 Study of Lyme Disease Vaccine

Valneva SE Announces Supervisory Board Member Appointments

Valneva SE announced that it expects to receive €90.627232 million in funding from Pfizer Inc.

Valneva SE announced that it expects to receive €90.627232 million in funding from Pfizer Inc.

Valneva Announces Board Appointments

Valneva Successfully Completes Lot-To-Lot Consistency Trial for Its Single-Shot Chikungunya Vaccine Candidate

Valneva Successfully Completes Lot-To-Lot Consistency Trial for Its Single-Shot Chikungunya Vaccine Candidate

EMA Accepts Filing of Marketing Authorization Application for Valneva's Inactivated COVID-19 Vaccine Candidate

Valneva SE Receives Emergency Use Authorization from the United Arab Emirates for its Inactivated COVID-19 Vaccine

Valneva SE Initiates Heterologous Booster Trial of Inactivated, Covid-19 Vaccine Candidate

Valneva SE, Annual General Meeting, Jun 23, 2022

Valneva Provides Regulatory Update on Its Inactivated Covid-19 Vaccine Candidate

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen